化学
骨髓纤维化
Janus激酶2
真性红细胞增多症
药理学
原发性血小板增多症
骨髓增生性疾病
激酶
癌症研究
生物化学
内科学
医学
骨髓
作者
Mark W. Ledeboer,Albert C. Pierce,John P. Duffy,Huai Gao,David Messersmith,Francesco G. Salituro,Suganthini Nanthakumar,Jon H. Come,Albert C. Pierce,Lora Swenson,Dina Shlyakter,Sudipta Mahajan,Thomas Hoock,Bin Fan,Wan-Jung Tsai,Elaine Kolaczkowski,Scott Carrier,James K. Hogan,Richard Zessis,S. Pazhanisamy,Youssef L. Bennani
标识
DOI:10.1016/j.bmcl.2009.10.053
摘要
Constitutive activation of the EPO/JAK2 signaling cascade has recently been implicated in a variety of myeloproliferative disorders including polycythemia vera, essential thrombocythemia and myelofibrosis. In an effort to uncover therapeutic potential of blocking the EPO/JAK2 signaling cascade, we sought to discover selective inhibitors that block the kinase activity of JAK2. Herein, we describe the discovery and structure based optimization of a novel series of 2-amino-pyrazolo[1,5-a]pyrimidines that exhibit potent inhibition of JAK2.
科研通智能强力驱动
Strongly Powered by AbleSci AI